Orlando Immunology Center Groundbreaking

by admin on October 16, 2012

Orlando Immunology Center groundbreakingOn Monday, October 15, the Studio 3 Designs team was on hand for the groundbreaking ceremony for the Orlando Immunology Center (OIC) expansion project. Commissioner Robert F. Stuart, City of Orlando District 3, was on hand to proclaim the day as “Orlando Immunology Center Day”. Pictured here is the design and build team, along with Commissioner Stuart and project owner, Dr. Edwin DeJesus.

The first phase of the project kicked off earlier this month with the demolition of the existing 1707 N. Mills Ave. building. Construction of a new three-story, state-of-the-art immunology clinic and research facility will begin shortly. Once construction is complete, the second phase will begin with the demolition of the existing OIC clinic at 1701 N. Mills Ave, making way for a new on-site pharmacy.

Together, the completed project will total 18,600 square feet. The expansion will allow OIC to provide comprehensive, cutting-edge treatment for an additional 2,000 people annually who are affected by hepatitis and HIV, including those with limited access to medical care. It will also allow further expansion of OIC’s nationally recognized phase I-IV clinical trial program and position the practice to conduct more advanced study types.

“We are very excited to have the opportunity to once again partner with Edward Woodill and his team at Studio 3 Designs,” said Dr. Edwin DeJesus, Owner and Medical Director. “The OIC team has the tools to deliver excellence in medical care, and Studio 3 Designs has the vision that allows us to provide that care in a sophisticated, professional, and highly efficient atmosphere.”

Orlando Immunology Center groundbreakingThe design of the OIC expansion presents several unique challenges for the design and build team. Due to the sensitive nature of infectious disease cases, the design will exceed standard HIPPA compliance measures for patient privacy while simultaneously presenting a warm, comforting environment. Additionally, the clinical research facility will include integrated security features that protect the proprietary nature of the clinical trials being conducted.

Leave a Comment

Previous post:

Next post: